SGYP Synergy Pharmaceuticals, Inc.

-0.15  -2.54%
Previous Close 5.91
Open 5.90
Price To book 88.21
Market Cap 1.04B
Shares 179,953,000
Volume 6,194,416
Short Ratio 4.12
Av. Daily Volume 4,769,470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. NDA filing due 1Q 2017.
Constipation-predominant irritable bowel syndrome (IBS-C)
Approved January 19, 2017.
Trulance (plecanatide)
Chronic idiopathic constipation (CIC)
Phase 1b data released January 2016. Phase 2 planned.
Mild-to-moderate ulcerative colitis

Latest News

  1. Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views
  2. 3:32 am Synergy Pharma confirms FDA approval for TRULANCE
  3. Synergy Pharmaceuticals Secures Approval for Linzess Competitor
  4. FDA OKs Synergy Pharmaceuticals Constipation Drug
  5. Synergy (SGYP) Trulance Wins FDA Approval for Constipation
  6. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  7. Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
  8. Synergy wins U.S. approval for constipation drug
  9. 5 Biotech Stocks You'll Want to Watch in the 1st Quarter
  10. Synergy Pharmaceuticals Inc (SGYP): A Top January Pick Ahead Of PDUFA
  11. Key FDA Events to Watch Out for in Q1
  12. 3 Little-Known Pharmaceutical Companies to Put on Your Radar
  13. Start the New Year off Right with 3 Best Biotech Stocks
  14. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  15. A David and Goliath Story: Can Small-Cap Synergy Pharmaceuticals Take on Ironwood Pharmaceuticals?
  16. Coverage initiated on Synergy Pharma by Oppenheimer
  17. Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
  18. Two Key FDA Decisions to Watch Out for in January 2017
  19. 3 Under-the-Radar Biotech Stocks to Watch in 2017
  20. SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers